Navigation Links
Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever
Date:7/15/2009

SAN DIEGO, July 15 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that its New Drug Application (NDA) for Acetavance(TM) (intravenous acetaminophen), its investigational product candidate for the treatment of acute pain and fever in adults and children, has been accepted for filing by the U.S. Food and Drug Administration (FDA) and designated for Priority Review. Priority Review is granted to those products that address significant unmet medical needs or have the potential to provide a significant improvement compared to marketed products and provides for a review period of six months from the date of NDA submission. The FDA has issued an action date for the NDA of November 13, 2009 under the Prescription Drug User Fee Act (PDUFA).

"We are very pleased with the FDA's decision to grant the Acetavance NDA a Priority Review, which we believe reflects the potential of Acetavance to fulfill a significant unmet need for a new class of intravenous medication to treat acute pain and fever in adults and children, for which there remains a large gap in the U.S. treatment paradigm," said Ted Schroeder, President and CEO of Cadence.

The Priority Review designation reduces the target review period for the NDA from ten months to six months. Acceptance of the NDA submission indicates that the FDA has made a threshold determination that the NDA is sufficiently complete to permit a substantive review.

The company's 505(b)(2) NDA for Acetavance includes data from one pivotal clinical trial for the treatment of acute pain in patients following orthopedic surgery and one pivotal clinical trial for the treatment of endotoxin-induced fever. The NDA is also supported by data from a total of nine placebo-controlled clinical trials, four active-controlled
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine news :

1. Cadence Pharmaceuticals Announces Appointment of Scott Byrd as Chief Commercial Officer
2. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Needham Life Sciences Conference in New York on June 11, 2009
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2009 Financial Results on May 7, 2009
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Cowen & Companys 29th Annual Health Care Conference in Boston on March 16, 2009
5. Cadence Pharmaceuticals Completes $86.6 Million Private Placement of Common Stock
6. Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIO CEO and Investor Conference in New York City
8. Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 in New York
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008
11. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2013)... Life science and analytical reagents are ... and create a new substance with the purpose of ... known as biotechnology reagents. Such reagents are significant in ... This market is driven by factors such as expansion ... therapeutics, growth in research and rapid commercialization of such ...
(Date:5/25/2013)... News) -- Many viruses and parasites that affect both ... a bacteria-borne illness than can result in liver or ... according to a veterinarian. These germs could ... air, said Dr. Susan Nelson, a clinical associate professor ... these serious diseases can be fatal, even with treatment," ...
(Date:5/25/2013)... 25, 2013 Studies from Johns Hopkins ... carrying excessive weight and their inability to get adequate ... losing weight can naturally relieve many symptoms. , ... in sleep quality was significantly associated with overall weight ... study dated November 6th, 2012, researchers monitored 77 ...
(Date:5/25/2013)... 25, 2013 Pradaxa lawsuits ... episodes of internal bleeding while using the blood thinner continue ... Court, Southern District of Illinois, Bernstein Liebhard LLP reports. ... side effect claims had been filed in the ... 705 claims reported by the Court on May 15th. ( ...
(Date:5/25/2013)... 25, 2013 According to a ... Market, 2013–2018", published by MarketsandMarkets is expected to ... of 5.54% which analyzes and studies the major ... Europe, Asia, and Rest of the World. , ... Tables , 87 Figures , ...
Breaking Medicine News(10 mins):Health News:Life Sciences And Analytical Reagents Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research 2Health News:Life Sciences And Analytical Reagents Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research 3Health News:Hidden Dangers Dog Dog Parks 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 3Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 4
... PITTSBURGH, April 29 Mylan Inc. (NYSE: ... Michael J. Monroe as senior vice,president - ... of the company,s senior,leadership team. In this ... and employee communications; corporate,branding/marketing; corporate media relations; ...
... also contributed to early dropout rate, study says , , ... problem drug users, and those not currently injecting drugs, ... a British study finds. , University of Kent and ... drug users in treatment programs and found that 25 ...
... Society finds cancer survivors who follow health behavior recommendations ... getting adequate exercisehave higher health-related quality of life (HRQoL) ... The study, which appears in the May issue of ... have low rates of smoking, but few are meeting ...
... factor most commonly used to predict whether an extremely ... that can help predict a preemies outcome have been ... Network, of which Yale is a member. , ... and whether the mother was given antenatal steroid mediation ...
... New York, NY -- A JDRF collaboration between Johns ... for the treatment of diabetic eye disease has performed ... using laser surgery. , These findings, representing the ... by The Johns Hopkins University, were presented Monday at ...
... Layoffs and Loss of Healthcare Services, PRINCETON, N.J., ... drives and longer waits for care.,Those are among the ... state,s $300 million in proposed healthcare cuts are approved., ... healthcare leaders from across,the state met with Gov. Jon ...
Cached Medicine News:Health News:Mylan Appoints Michael J. Monroe Senior Vice President for Global Public Affairs 2Health News:Youngest Drug Users Most Likely to Leave Treatment Programs 2Health News:Cancer survivors who practice healthy habits have higher quality of life 2Health News:Factors affecting survival, disability of extremely premature infants identified 2Health News:Promising early evidence of the superior benefits of drug therapy for diabetic eye disease 2Health News:Hospital CEOs Meet with Governor on Budget Cuts 2
(Date:5/23/2013)...  The need to add tissue preserving therapies ... prominently at the 108 th Annual Meeting ... Diego.  According to SonaCare Medical, a leader in ... the need for image-guided technologies to better identify ... minimally invasive ablative treatments, was addressed in the ...
(Date:5/23/2013)... , May 23, 2013  Hologic, Inc. ... ), a leading developer, manufacturer and supplier of ... with an emphasis on serving the healthcare needs ... observational study in a U.S. clinical practice comparing ... (breast tomosynthesis) with conventional 2D mammography alone showed ...
(Date:5/23/2013)... N.M. , May 23, 2013  Net Medical ... the telemedicine market, announced today the company has signed ... telemedicine staffing company based in Huntsville, AL ... that specializes in the staffing and recruitment of telemedicine ... completion of the final agreement, which is expected by ...
Breaking Medicine Technology:Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 2Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 3Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 4Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 5Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 6First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 2Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 3
... HAIFA, Israel, October 26 Cardio Vascular,Medical Device Corp. ... today released a brief shareholders update. , ... patent for an innovative,next-generation "steerable guidewire" applicable for all ... become the guidewire of,choice for surgeons throughout the world. ...
... Oct. 26 Symmetry Medical Inc. (NYSE: SMA ... global orthopaedic device industry and other medical markets, announced ... Based on recent diminished order flow resulting from lower ... in both orthopaedic and non-orthopaedic markets, Symmetry is adjusting ...
Cached Medicine Technology:Cardio Vascular Medical Device Sends Update to Shareholders 2Symmetry Medical Updates Full Year 2009 Financial Guidance 2Symmetry Medical Updates Full Year 2009 Financial Guidance 3
... Kendall provides hospitals and alternate care ... tracheostomy care trays which offer the ... control. Designed with the guidance of ... trays provide exactly what is required ...
... alternate care facilities with a wide ... offer the finest in nursing convenience ... guidance of experienced nursing personnel, these ... is required for efficient and quick ...
... KIMBERLY-CLARK BALLARD Component Kit ... Elbows and Double Swivel ... Customer-oriented presentation to meet ... Also available in neonatal ...
Indications For Usage: ,Bypass upper airway obstructions, provide long term ventilation, support and/or manage tracheal/bronchial secretions....
Medicine Products: